Q-omics provides the consensus-scored LCE1C profile across patient tissues and cancer cell-line models. LCE1C expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, LCE1C is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, LCE1C RNA expression shows 8,113 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KICH, KIRC, and ESCA as cancer lineages where LCE1C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LCE1C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LCE1C survival associations across molecular data types. LCE1C RNA expression shows survival associations in the most cancer types (19), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LCE1C RNA expression–survival associations across cancer types. High LCE1C expression shows unfavorable associations in KICH, MESO, THYM and SCLC, but favorable associations in LGG and CESC. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for LCE1C RNA expression.
This table summarizes LCE1C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LCE1C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LCE1C shows lower tumor expression in KIRC, KICH, KIRP, PRAD and BRCA and higher tumor expression in LUSC. The KIRC box plot shows higher LCE1C RNA expression in normal versus tumor tissue (log2 FC = −0.229, t-test p < 0.001).
This table shows molecular features associated with LCE1C in patient tissues and cancer cell lines. In patient samples, LCE1C shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set. In cancer cell lines, LCE1C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
